Clinical Trials Browser

Triple Negative Breast Neoplasms × pertuzumab × 90 days × Clear all

Breast Neoplasms, Triple Negative Breast Neoplasms

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms